Researchers at Banner Health's Sun Health Research Institute have discovered that Alzheimer's disease (AD) may be clinically confirmed in patients who have apolipoprotein E2 homozygote, following a study into the illness.
Marwan Sabbagh, Sun Health Research Institute's chief medical and scientific officer, and lead investigator of the study, said that the research may prove important in understanding how Alzheimer's genetics operate.
"Clinical diagnosis of possible AD has now become extremely accurate and is especially helpful to physicians looking for the best outcomes in treating patients," Mr Sabbagh commented.
He added that the study, which was published in the January 2009 issue of the Journal of Alzheimer's Disease, will allow new questions to be asked and answers to be gained.
MRI, PET and neuropsychological analysis and testing confirmed the findings of the apolipoprotein E2 homozygote Alzheimer's disease, while AD pathology has not yet been determined.
Earlier this month, it was announced that new research suggests a variant in a gene on the X chromosome is related to a heightened risk of AD in women.
Please click here for advice to help you find the right type of care.